✦ LIBER ✦

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias

✍ Scribed by Taira Maekawa; Eishi Ashihara; Shinya Kimura

Book ID: 106284998
Publisher: Springer
Year: 2007
Tongue: English
Weight: 495 KB
Volume: 12
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-007-0699-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Philadelphia-chromosome-pos

Treatment of Philadelphia-chromosome-positive human leukemia in scid mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor

✍ Yoshio Honma; Yoshinobu Matsuo; Yasuhide Hayashi; Satoshi Omura 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 731 KB

The molecular basis of the Philadelphia chromosome (Ph') is a structurally altered c-abl (bcr-abl) gene which encodes an abnormally large protein with protein tyrosine kinase activity. Herbimycin A, which effectively reduced intracellular phosphorylation by bcr-abl tyrosine kinase, preferentially in

ABL-specific tyrosine kinase inhibitor i

ABL-specific tyrosine kinase inhibitor imatinib as salvage therapy in a child with Philadelphia chromosome-positive acute mixed lineage leukemia (AMLL)

✍ Selle, B; Bär, C; Hecker, S; Schmidt-Rohr, U; Viehmann, S; Debatin, K-M; Reinhar 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 146 KB

Selective induction of apoptosis in Phil

Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148

✍ Dan, Shingo; Naito, Mikihiko; Tsuruo, Takashi 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 272 KB

Phase 1 study of INNO-406, a dual Abl/Ly

Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

✍ Hagop Kantarjian; Phillipp le Coutre; Jorge Cortes; Javier Pinilla-Ibarz; Arnon 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 226 KB

Synergistic activity of the new ABL-spec

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

✍ Topaly, J; Zeller, W J; Fruehauf, S 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 138 KB

Effects of the Tyrosine Kinase Inhibitor

Effects of the Tyrosine Kinase Inhibitor Imatinib Mesylate on a Bcr-Abl-Positive Cell Line: Suppression of Autonomous Cell Growth but No Effect on Decreased Adhesive Property and Morphological Changes

✍ Toshio Nishihara; Yasuo Miura; Yumi Tohyama; Chisato Mizutani; Terutoshi Hishita 📂 Article 📅 2003 🏛 Carden Jennings Publishing 🌐 English ⚖ 712 KB